SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:
Aerocrine AB (STO:AEROB) is pleased to announce the following organizational changes:
Morten Högholm Pedersen, MD PhD, will be joining the company in the role of Chief Technology Officer effective June 1st. Morten comes to Aerocrine from GN Otometrics A/S in Denmark where he held a number of different positions, most recently as VP Global R&D and Product Management. It is expected that his background in technology and technology development will further the development of the NIOX family of products including work currently underway to explore the home market. Morten will report to Scott Myers, CEO of Aerocrine.
Caroline Andersson, Aerocrine’s General Counsel is being promoted to membership in Aerocrine’s Executive Leadership Team effective immediately as recognition for her continued contribution to the business. Caroline will report to Marshall Woodworth, CFO of Aerocrine. In addition to her other duties and responsibilities Caroline will continue to serve in her role as secretary to the Board of Directors.
Ken Marshall, President of Aerocrine Inc. and VP of Global Marketing will be leaving Aerocrine and the management group effective April 30th. The roles that Ken filled will be handled by other members of the Executive Leadership team including Scott Myers who will be directly overseeing US Operations. Aerocrine wishes to thank Ken for his many contributions to the growth and success of the company and wishes him well in his future endeavors.
Following these moves the Executive Leadership Team of Aerocrine will be comprised of seven members:
Scott Myers, President and CEO
Caroline Andersson, General Counsel
Mats Carlson, VP of Global Business Operations
Dr. Morten Pedersen, Chief Technology Officer
David Plotts, VP International Sales and Marketing
Dr. Kathy Rickard, Chief Medical Officer
Marshall Woodworth, Chief Financial Officer
‘The hiring of Morten, the promotion of Caroline, and the further streamlining of our organization will better prepare Aerocrine to accomplish our long range goals’ said Aerocrine’s CEO Scott Myers.
Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® and NIOX VERO®, which enables fast and reliable point-of-care measurement of airway inflammation. These products play a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com.
This information was brought to you by Cision http://news.cision.com